Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Interim Analysis of Safety Outcomes during Treatment with Eculizumab: Results from the International Paroxysmal Nocturnal Hemoglobinuria Registry

Anita Hill, MBChB (Hons), PhD, Alexander Roeth, MD, Gérard Socié, MDPhD, Marie-Pierre Caby-Tosi, PharmD, PhD, Amanda Wilson, MPH, PhD, Philippe Gustovic, MD, Camille L. Bedrosian, MD, Robert A. Brodsky, MD

Blood (2017) 130 (Supplement 1): 3486.

https://doi.org/10.1182/blood.V130.Suppl_1.3486.3486

Published: 2017

Journal Articles

Clinical Benefit of Eculizumab in Patients with No Transfusion History in the International Paroxysmal Nocturnal Hemoglobinuria Registry

Antonio Medina Almeida, MD PhD, Camille L. Bedrosian, MD, Alexander Cole, DSc, MPH, Petra Muus, MD PhD, Hubert Schrezenmeier, MD, Jeff Szer, MB, BS, FRACP, Alvaro Urbano-Ispizua, MD PhD, Wendell F. Rosse, MD

Blood (2015) 126 (23): 3340.

https://doi.org/10.1182/blood.V126.23.3340.3340

Published: 2015

Journal Articles

Eculizumab Inhibits Thrombotic Microangiopathy and Improves Renal Function in Pediatric Patients with Atypical Hemolytic Uremic Syndrome: 1-Year Update

Laurence A. Greenbaum, MDPhD, Marc Fila, MD PhD, Gianluigi Ardissino, MD PhD, Samhar I. Al-Akash, MD, Jonathan H Evans, MD, Kenneth Lieberman, MD, Silvio Maringhini, MD, Lars Pape, MD, Lesley Rees, MD FRCPCH, Nicole C.A.J. van de Kar, MD PhD, Johan Vande Walle, MD PhD, Masayo Ogawa, MD FAAP, Camille L. Bedrosian, MD, Christoph Licht, MD FRCP(C), FASN

Blood (2014) 124 (21): 4986.

https://doi.org/10.1182/blood.V124.21.4986.4986

Published: 2014

Journal Articles

Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Pediatric and Adult Patients with or without Identified Genetic Complement Mutations or Complement Factor H Autoantibodies

Spero R Cataland, MD, Thorsten Feldkamp, MD, Camille L. Bedrosian, MD, John Kincaid, MD MA, Enrico E. Minetti, MD

Blood (2014) 124 (21): 2789.

https://doi.org/10.1182/blood.V124.21.2789.2789

Published: 2014

Journal Articles

Time To Hematologic and Renal Improvements In aHUS Patients With Progressing Thrombotic Microangiopathy Treated With Eculizumab Over Two Years

Petra Muus, MD, PhD, Camille L. Bedrosian, MD, Richard R. Furman, MD, Christophe Legendre, Chantel Loirat

Blood (2013) 122 (21): 3426.

https://doi.org/10.1182/blood.V122.21.3426.3426

Published: 2013

Journal Articles

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Adult Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Fadi Fakhouri, Maryvonne Hourmant, MD, Spero R. Cataland, M.D., Mario Espinosa, A. Osama Gaber, Jan Menne, Enrico Minetti, Francois Provot, Eric Rondeau, Piero Ruggenenti, Laurent Weekers, Masayo Ogawa, MD, FAAP, Camille L. Bedrosian, MD, Christophe Legendre

Blood (2013) 122 (21): 2179.

https://doi.org/10.1182/blood.V122.21.2179.2179

Published: 2013

Journal Articles

Biomarkers Of Complement and Endothelial Activation, Inflammation, Thrombosis and Renal Injury In Patients (pts) With aHUS Treated With Eculizumab (ECU)

Roxanne Cofiell, Anjli Kukreja, PhD, Krystin Bedard, Yan Yan, Angela Mickle, Masayo Ogawa, MD, FAAP, Camille L. Bedrosian, MD, Susan Faas, PhD

Blood (2013) 122 (21): 2184.

https://doi.org/10.1182/blood.V122.21.2184.2184

Published: 2013

Journal Articles

Time To Hematologic and Renal Improvements In Atypical Hemolytic Uremic Syndrome Patients With Long Disease Duration and Chronic Kidney Disease (CKD) Treated With Eculizumab

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe Legendre, Yahsou Delmas, MD, Maria Herthelius, MD, Camille L. Bedrosian, MD, Chantel Loirat

Blood (2013) 122 (21): 2186.

https://doi.org/10.1182/blood.V122.21.2186.2186

Published: 2013

Journal Articles

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Pediatric Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Larry Greenbaum, MD, Marc Fila, Gianluigi Ardissino, Samhar Al-Akash, Jonathan Evans, Paul Henning, Kenneth Lieberman, Silvio Maringhini, Lars Pape, Lesley Rees, Nicole Kar, Johan Vande Walle, Masayo Ogawa, MD, FAAP, Camille L. Bedrosian, MD, Christoph Licht, MD

Blood (2013) 122 (21): 2191.

https://doi.org/10.1182/blood.V122.21.2191.2191

Published: 2013

Journal Articles

Eculizumab Protects Against TE and Prolongs Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Study

Gérard Socié, MD PhD, Hubert Schrezenmeier, MD, Petra Muus, MD, PhD, Jeffrey Szer, MBBS, Alvaro Urbano-Ispizua, MD, Jaroslaw P. Maciejewski, MD, PhD, Robert A. Brodsky, MD, Monica Bessler, MD, PhD, Yuzuru Kanakura, MD, PhD, Wendell F. Rosse, MD, Gus Khursigara, PhD, Camille L. Bedrosian, MD, Peter Hillmen, MBChB, PhD

Blood (2012) 120 (21): 3480.

https://doi.org/10.1182/blood.V120.21.3480.3480

Published: 2012

Journal Articles

Eculizumab (ECU) in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Progressing Thrombotic Microangiopathy (TMA): 2-Year Data.

Larry Greenbaum, MD, Christophe M. Legendre, MD, Sunil Babu, MD, Richard R. Furman, MD, Neil Sheerin, MD, David Cohen, MD, Frank Eitner, MD, Yahsou Delmas, MD, Camille L. Bedrosian, MD, Chantal Loirat, MD

Blood (2012) 120 (21): 2084.

https://doi.org/10.1182/blood.V120.21.2084.2084

Published: 2012

Journal Articles

Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Patients with or without Identified Genetic Complement Mutations or Complement Factor H Auto-Antibodies.

Samhar I. Al-Akash, Timothy H. J. Goodship, MD, Richard J. H. Smith, MD, Christophe M. Legendre, MD, Christoph Licht, MD, Petra Muus, MD, PhD, Camille L. Bedrosian, MD, Veronique Frémeaux-Bacchi, PhD, Chantal Loirat, MD

Blood (2012) 120 (21): 2085.

https://doi.org/10.1182/blood.V120.21.2085.2085

Published: 2012

Journal Articles

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe M. Legendre, MD, Kenneth W. Douglas, MD, Maryvonne Hourmant, MD, Yahsou Delmas, MD, Maria Herthelius, MD, Antonella Trivelli, MD, Timothy H. J. Goodship, MD, Camille L. Bedrosian, MD, Chantal Loirat, MD

Blood (2012) 120 (21): 985.

https://doi.org/10.1182/blood.V120.21.985.985

Published: 2012

Journal Articles

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe Legendre, MD, Kenneth W Douglas, MD, Maryvonne Hourmant, MD, Yahsou Delmas, MD, Maria Herthelius, MD, Antonella Trivelli, MD, Timothy H. J. Goodship, MD, Camille L Bedrosian, MD, Chantal Loirat, MD

Blood (2011) 118 (21): 3303.

https://doi.org/10.1182/blood.V118.21.3303.3303

Published: 2011

Journal Articles

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study

Larry Greenbaum, MD, Sunil Babu, MD, Richard R. Furman, MD, Neil Sheerin, MD, David Cohen, MD, Osama Gaber, MD, Frank Eitner, MD, Yahsou Delmas, MD, Chantal Loirat, MD, Camille L Bedrosian, MD, Christophe Legendre, MD

Blood (2011) 118 (21): 193.

https://doi.org/10.1182/blood.V118.21.193.193

Published: 2011

Journal Articles

Clinical Characteristics of Classic Paroxysmal Nocturnal Hemoglobinuria (PNH) in Pediatric Patients: A Comparison with Classic PNH in Adults. An International PNH Registry Study

Alvaro Urbano-Ispizua, MD, Hubert Schrezenmeier, MD, Petra Muus, MD, PhD, Jaroslaw P Maciejewski, MD, PhD, Gérard Socié, Jeffrey Szer, MBBS, FRACP, Robert A. Brodsky, MD, Monica Bessler, MD, PhD, Wendell F Rosse, MD, Yuzuru Kanakura, Gus Khursigara, PhD, Camille L Bedrosian, MD, Peter Hillmen, MBChB, PhD

Blood (2011) 118 (21): 2102.

https://doi.org/10.1182/blood.V118.21.2102.2102

Published: 2011

Journal Articles

Eculizumab (ECU) Significantly Improves Health-Related Quality of Life (HRQoL) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Petra Muus, MD, PhD, Christoph Licht, MD, Tim H. J. Goodship, MD, Larry Greenbaum, MD, Camille L Bedrosian, MD, Chantal Loirat, MD, Christophe Legendre, MD

Blood (2011) 118 (21): 4772.

https://doi.org/10.1182/blood.V118.21.4772.4772

Published: 2011

Journal Articles

Use of Blood Transfusions In Paroxysmal Nocturnal Hemoglobinuria Patients with and without Aplastic Anemia Enrolled In the Global PNH Registry

Hubert Schrezenmeier, Robert A Brodsky, MD, Petra Muus, MD, PhD, Monica Bessler, MD, PhD, Jeffrey Szer, MBBS, FRACP, Jaroslaw P Maciejewski, MD, PhD, FACP, Gérard Socié, Alvaro Urbano-Ispizua, MD, Yuzuru Kanakura, MD, PhD, Britta Hoechsmann, Wendell F Rosse, MD, Gus Khursigara, PhD, Anders Karnell, MD, PhD, Camille L Bedrosian, MD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 2241.

https://doi.org/10.1182/blood.V116.21.2241.2241

Published: 2010

Journal Articles

Evaluation of Paroxysmal Nocturnal Hemoglobinuria Disease Burden: The Patient's Perspective. A Report From the International PNH Registry.

Petra Muus, MD, PhD, Jeffrey Szer, MBBS, FRACP, Hubert Schrezenmeier, MD, Professor, Robert A Brodsky, MD, Monica Bessler, MD, PhD, Gérard Socié, Alvaro Urbano-Ispizua, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Wendell F Rosse, MD, Yuzuru Kanakura, MD, PhD, Gus Khursigara, PhD, Anders Karnell, MD, PhD, Camille L Bedrosian, MD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 1525.

https://doi.org/10.1182/blood.V116.21.1525.1525

Published: 2010

Journal Articles

First-In-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) In Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM)

Daruka Mahadevan, MD, PhD, Mark C Lanasa, MD, PhD, Maria Whelden, RN, Susan J Faas, PhD, Terrie L Ulery, PhD, Anjli Kukreja, PhD, Lan Li, MS, MD, Camille L Bedrosian, MD, Leonard T Heffner, MD

Blood (2010) 116 (21): 2465.

https://doi.org/10.1182/blood.V116.21.2465.2465

Published: 2010

NARROW

Interim Analysis of Safety Outcomes during Treatment with Eculizumab: Results from the International Paroxysmal Nocturnal Hemoglobinuria Registry

Clinical Benefit of Eculizumab in Patients with No Transfusion History in the International Paroxysmal Nocturnal Hemoglobinuria Registry

Eculizumab Inhibits Thrombotic Microangiopathy and Improves Renal Function in Pediatric Patients with Atypical Hemolytic Uremic Syndrome: 1-Year Update

Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Pediatric and Adult Patients with or without Identified Genetic Complement Mutations or Complement Factor H Autoantibodies

Time To Hematologic and Renal Improvements In aHUS Patients With Progressing Thrombotic Microangiopathy Treated With Eculizumab Over Two Years

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Adult Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Biomarkers Of Complement and Endothelial Activation, Inflammation, Thrombosis and Renal Injury In Patients (pts) With aHUS Treated With Eculizumab (ECU)

Time To Hematologic and Renal Improvements In Atypical Hemolytic Uremic Syndrome Patients With Long Disease Duration and Chronic Kidney Disease (CKD) Treated With Eculizumab

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Pediatric Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Eculizumab Protects Against TE and Prolongs Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Study

Eculizumab (ECU) in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Progressing Thrombotic Microangiopathy (TMA): 2-Year Data.

Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Patients with or without Identified Genetic Complement Mutations or Complement Factor H Auto-Antibodies.

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study

Clinical Characteristics of Classic Paroxysmal Nocturnal Hemoglobinuria (PNH) in Pediatric Patients: A Comparison with Classic PNH in Adults. An International PNH Registry Study

Eculizumab (ECU) Significantly Improves Health-Related Quality of Life (HRQoL) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Use of Blood Transfusions In Paroxysmal Nocturnal Hemoglobinuria Patients with and without Aplastic Anemia Enrolled In the Global PNH Registry

Evaluation of Paroxysmal Nocturnal Hemoglobinuria Disease Burden: The Patient's Perspective. A Report From the International PNH Registry.

First-In-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) In Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only